Therapeutic strategies in autoimmune diseases;Strategies therapeutiques au cours des maladies auto-immunes

Annales de l'Institut Pasteur/Actualites

Volumn 7, Issue 2, 1996, Pages 147-151

  Karmochkine, Marina ^a   Kazatchkine, Michel ^a  

^a HÔPITAL BROUSSAIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; RAPAMYCIN; TACROLIMUS; VACCINE;

AUTOIMMUNITY; B LYMPHOCYTE; DRUG THERAPY; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; REVIEW; T LYMPHOCYTE; VACCINATION;

EID: 0030469412     PISSN: 09244204     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-4204(97)85210-9     Document Type: Article

References (25)

1. 1 Boumpas DT, Paliogianni F, Anastassiou ED, Balow JE (1991) Glucocorticosteroid action on the immune system: molecular and cellular aspects. Clin Exp Rheumatol 9, 413-423
2. 2 Chatenoud L (1994) Use of CD3 antibodies in transplantation and autoimmune diseases. Transplant Proc 26, 3191-3193
3. 3 Chen Y, Inobe JI, Marks R, Gonnella P, Kuchroo VK, Weiner HL (1995) Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 376, 177-180
4. 4 Desquenne CL, Esch TR, Otvos LJ, Heber KE (1991) T-cell receptor peptide immunization leads to enhanced and chronic experimental allergic encephalomyelitis. Proc Natl Acad USA 88, 7219-7223
5. 5 Elliott MJ, Maini RN, Feldmann M, et al (1994) Randomized double-bind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet 344, 1105-1110
6. 6 Finck BK, Linsley PS, Wofsy D (1994) Treatment of murine lupus with CTLA4Ig. Science 265, 1225-1227
7. 7 Friedman A, Weiner HL (1994) Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc Natl Acad USA 91, 6688-6692
8. 8 Guery JC, Sette A, Leighton J, Dragomir A, Adorini L (1992) Selective immunosuppression by administration of major histocompatibility complex (MHC) class II-binding peptides. Evidence for in vivo MHC-blockade preventing T cell activation. J Exp Med 175, 1345-1352
9. 9 Jameson SC, Bevan MJ (1995) T cell receptor antagonists and partial agonists. Immunity 2, 1-11
10. 10 Kakimoto K, Katsuki M, Hirofuji T, Iwata H, Koga T (1988) Isolation of T cell line capable of protecting mice against collagen-induced arthritis. J Immunol 140, 78-83
11. 11 Kavanaugh AF, Davis LS, Nichols LA, et al (1994) Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 37, 992-996
12. 12 Kazatchkine MD, Dietrich G, Hurez V, et al (1994) V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (IVIg). Immunol Rev 139, 79-107
13. 13 Kunicka JE, Talle MA, Denhardt G et al (1993) Immunosuppression by glucocorticoids: inhibition of production of multiple lymphokines by in vivo administration of dexamethasone. Cell Immunol 149, 39-49
14. 14 Marmont AM, Van Bekkum DW (1995) Stem cell transplantation for severe autoimmune diseases: new proposals but still unanswered questions. Bone Marrow Transplant 16, 497-498
15. 15 Mor F, Cohen IR (1995) Vaccines to prevent and treat autoimmune diseases. Int Arch Allerg Immunol 108, 345-349
16. 16 Moreland LW, Pratt PW, Bucy RP, Jackson BS, Feldman JW, Koopman WJ (1994) Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody. Arthritis Rheum 37, 834-838
17. 17 Sartor RB (1994) Cyclosporine therapy for inflammatory bowel disease. N Engl J Med 330, 1897-1898
18. 18 Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS (1995) Role of transcriptional activation of IkBa in mediation of immunosuppression by glucocorticoids. Science 270, 283-286
19. 19 Schreiber SL, Crabtree GR (1992) The mechanism of action of cyclosporin A and FK506. Immunol Today 13, 136-142
20. 20 Steinberg AD, Steinberg SC (1991) Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 34, 945-950
21. 21 Thompson CB (1995) Apoptosis in the pathogenesis and treatment of disease. Science 267, 1456-1462
22. 22 Vandenbark AA, Hashim G, Offner H (1989) Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature 341, 541-544
23. 23 Waldmann TA (1991) Monoclonal antibodies in diagnosis and therapy. Science 252, 1657-1662
24. 24 Weinblatt ME (1995) Methotrexate for chronic diseases in adults. N Engl J Med 333, 330-331
25. 25 Weiner HL, Friedman A, Miller A, et al (1994) Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev lmmunol 12, 809-837